By: Justice in MI
Despite being the lefty that I am, I don’t quite get the one-drug-per-class issue. Particularly, among generics. For example, for statins, why not have generic simva, atora, lova, meva etc. The reality...
View ArticleBy: MC RPh
It doesn’t matter in classes that are all or mostly generic. It matters when the only options are branded products. It probably does not prevent a plan from putting a prior auhtorization on one or both...
View ArticleBy: Ben
It would be nice if one of the tickets to admission onto the formulary or plan was a requirement to publish complete clinical trials. Then the consumer and health professional would have a fighting...
View Article
More Pages to Explore .....
